Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG [PGG glucan] Injection in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Feb 2016
At a glance
- Drugs PGG-glucan (Primary)
- Indications Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Postoperative infections
- Focus Adverse reactions
- Sponsors Biothera
- 25 Feb 2016 Results published in Investigational New Drugs: The Journal of New Anticancer Agents, as per Biothera media release.
- 25 Feb 2016 Results published in Biothera media release.
- 31 Oct 2008 Data will be presented at the International Society for Biological Therapy of Cancer on 01 November 2008.